Fibrous bodies are associated with lower GH production and decreased expression of E-cadherin in GH-producing pituitary adenomas
- PMID: 14974920
- DOI: 10.1046/j.1365-2265.2003.01921.x
Fibrous bodies are associated with lower GH production and decreased expression of E-cadherin in GH-producing pituitary adenomas
Abstract
Objective: A retrospective study was conducted in order to elucidate the clinicopathological significance of fibrous bodies, a hallmark of the sparsely granulated variant of GH-producing pituitary adenomas.
Methods: A total of 37 acromegalic patients, 14 men and 23 women, with pure GH adenomas were studied. Immunohistochemistry was performed with antibodies specific for cytokeratin 8 and 18 (CAM5.2), GH, prolactin and E-cadherin. The tumour volume was estimated with high-resolution magnetic resonance imaging.
Results: The percentages of adenoma cells with dot-like immunoreactivity for CAM5.2, fibrous bodies, were variable, ranging continuously from 0 to 100%. An increased percentage was associated with a lower basal GH level per unit tumour volume, a lower GH response to a bromocriptine suppression test, decreased immunoreactivities for GH and prolactin, and a decreased expression of E-cadherin immunoreactivity.
Conclusion: GH adenomas could not be distinctly separated into those with or without fibrous bodies. Decreased expression of E-cadherin may be involved in formation of fibrous bodies and result in lower GH production.
Similar articles
-
Significance of immunohistochemical expression of Rab3B and SNAP-25 in growth hormone-producing pituitary adenomas.Acta Neuropathol. 2005 Jun;109(6):598-602. doi: 10.1007/s00401-005-1008-6. Epub 2005 May 13. Acta Neuropathol. 2005. PMID: 15895198
-
Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas.Agents Actions Suppl. 1992;38 ( Pt 2):175-82. Agents Actions Suppl. 1992. PMID: 1462825
-
Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation.Radiology. 2003 Aug;228(2):533-8. doi: 10.1148/radiol.2282020695. Epub 2003 Jun 20. Radiology. 2003. PMID: 12819334
-
Down-regulation of E-cadherin and catenins in human pituitary growth hormone-producing adenomas.Front Horm Res. 2004;32:127-32. doi: 10.1159/000079041. Front Horm Res. 2004. PMID: 15281343 Review.
-
Preoperative identification of clearly separated double pituitary adenomas.Clin Endocrinol (Oxf). 2004 Jul;61(1):26-30. doi: 10.1111/j.1365-2265.2004.02055.x. Clin Endocrinol (Oxf). 2004. PMID: 15212641 Review.
Cited by
-
Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary.Pituitary. 2017 Feb;20(1):84-92. doi: 10.1007/s11102-016-0748-8. Pituitary. 2017. PMID: 27586499 Review.
-
Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype.Pituitary. 2015 Jun;18(3):326-34. doi: 10.1007/s11102-014-0578-5. Pituitary. 2015. PMID: 24925503
-
Fibrous bodies in pituitary adenoma.Med J Armed Forces India. 2024 Dec;80(Suppl 1):S430-S432. doi: 10.1016/j.mjafi.2024.02.005. Epub 2024 Apr 8. Med J Armed Forces India. 2024. PMID: 39734841 No abstract available.
-
Association of Pathology Markers with Somatostatin Analogue Responsiveness in Acromegaly.Int J Endocrinol. 2022 Sep 26;2022:8660470. doi: 10.1155/2022/8660470. eCollection 2022. Int J Endocrinol. 2022. PMID: 36199813 Free PMC article.
-
Clinical Impact of the Current WHO Classification of Pituitary Adenomas.Endocr Pathol. 2016 Jun;27(2):104-14. doi: 10.1007/s12022-016-9418-7. Endocr Pathol. 2016. PMID: 26860936 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous